Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Serene Francis

Rheumatology Roswell, GA Medical Doctor

NPI 1366608770 CMS profile 152424

11685 Alpharetta Hwy, Suite120, Roswell, GA 30076

Open in the dashboard

General payments

$10,574

652 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Serene Francis of Roswell, GA is reported in the CMS Open Payments database as having received $10,574 across 652 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,978 163
2024 General $2,097 136
2023 General $1,592 97
2022 General $1,779 126
2021 General $701 42
2020 General $330 19
2019 General $1,095 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Serene Francis
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Serene Francis were reported at $2,978. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Serene Francis Rheumatology median Middle half National median
2019 $1,095 $744 $153–$2,687 $163
2020 $330 $462 $98–$2,027 $114
2021 $701 $531 $101–$2,153 $132
2022 $1,779 $627 $125–$2,303 $149
2023 $1,592 $741 $145–$2,524 $160
2024 $2,097 $830 $166–$2,660 $164
2025 $2,978 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,603 176 payments
  2. Novartis Pharmaceuticals Corporation $2,338 186 payments
  3. Amgen Inc. $1,410 80 payments
  4. Janssen Biotech, Inc. $871 50 payments
  5. Horizon Therapeutics plc $409 18 payments
  6. UCB, Inc. $391 22 payments
  7. Radius Health, Inc. $390 19 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $328 14 payments
  9. Pfizer Inc. $314 17 payments
  10. AstraZeneca Pharmaceuticals LP $276 8 payments
  11. Other $1,245 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,574 652 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,546 115 payments
  2. COSENTYX Dermatology $1,420 103 payments
  3. COSENTYX Immunology $1,087 98 payments
  4. TREMFYA $624 36 payments
  5. SKYRIZI $612 35 payments
  6. Otezla $403 22 payments
  7. OFEV $387 19 payments
  8. SIMPONI ARIA $382 23 payments
  9. KRYSTEXXA $367 15 payments
  10. Enbrel $318 23 payments
  11. Other $5,094 261 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

2,019

Median for Rheumatology: 1,511

Drug cost

$1,750,886

Median for Rheumatology: $1,139,948

Branded share of claims

24.2%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 75 $559,681
Enbrel Sureclick Etanercept Brand 40 $295,451
Enbrel Mini Etanercept Brand 23 $168,860
Rinvoq Upadacitinib Brand 23 $149,396
Actemra Actpen Tocilizumab Brand 27 $135,218
Prolia Denosumab Brand 73 $125,885
Orencia Abatacept/Maltose Brand 26 $87,556
Orencia Abatacept Brand 11 $61,575
Tymlos Abaloparatide Brand 14 $56,413
Saphnelo Anifrolumab-Fnia Brand 11 $55,671

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$1,222,496

Of which drugs: $1,043,623

Medicare patients

400

Average age 75

Services billed

53,375

333 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Osteoporosis 44%
Ischemic heart disease 29%
Diabetes 21%
Chronic kidney disease 21%
Depression 20%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 14 6,725 $227,418
Injection, denosumab, 1 mg J0897 Office 70 6,600 $134,699
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 20 121 $87
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 12 10 $50

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COSENTYX
$520 — —
RINVOQ
$401 23 —
SKYRIZI
$247 — —
TREMFYA
$190 — —
Enbrel
$128 63 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

652 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record